Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Fax: 31 71 524 7445

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

Gabriel1234 Oct. 23 at 7:09 PM

$PHAR https://www.marketwatch.com/investing/stock/phar

0 · Reply

Gabriel1234 Oct. 20 at 9:57 PM

$PHAR Positive results highlighted: The press release specifically mentions “positive new clinical, economic, and comparative data” — implying that results are favorable and could support stronger positioning versus competitors (e.g., Sebetralstat for HAE). Broader awareness: Presenting at ACAAI boosts visibility among specialists, potentially helping future prescriptions and market adoption for both drugs. Long-term signal: It strengthens Pharming’s reputation in rare disease research, which could attract new partnerships or clinical collaborations.

1 · Reply

Gabriel1234 Oct. 20 at 9:56 PM

$PHAR Scientific recognition: Having 12 abstracts accepted at a major international conference (ACAAI 2025) demonstrates strong recognition of Pharming’s research quality and scientific credibility in rare diseases. Pipeline strength: The data covers both of Pharming’s marketed drugs — RUCONEST®, already approved for hereditary angioedema (HAE) Joenja® (leniolisib), approved for APDS — and shows ongoing clinical, real-world, and economic research, suggesting continued development and relevance.

0 · Reply

Gabriel1234 Oct. 20 at 9:55 PM

$PHAR Pharming Group N.V. announced that 12 scientific abstracts have been accepted for presentation at the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida (November 6–10, 2025). Five posters will share new data on RUCONEST® for the on-demand treatment of hereditary angioedema (HAE), while seven focus on Joenja® (leniolisib) and its real-world effectiveness in treating APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome). The studies highlight clinical outcomes, cost-effectiveness, quality of life, and patient/caregiver experiences.Pharming’s Chief Medical Officer, Anurag Relan, emphasized that these presentations reflect the company’s commitment to advancing care for patients with rare diseases.

0 · Reply

Gabriel1234 Oct. 20 at 1:55 PM

$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-presentations-at-2025-acaai-annual-scientific-meeting-showcasing-new-data-across-rare-disease-portfolio-07005207?mod=mw_quote_news_seemore

0 · Reply

Thestocktraderhubzee Oct. 20 at 10:02 AM

WATCHLIST OCT 20 2025 $NVO FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event $SNY AlphaMedix Shows Durable, Clinically Meaningful Responses In Advanced GEP-NETs, Meeting All Primary Endpoints In Phase 2 Study $IOBT IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance $PHAR Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases $STM STMicroelectronics Introduces Four New 5MP BrightSense Image Sensors For Industrial Automation, Security, And Smart Retail Applications

0 · Reply

Ruconestor Oct. 15 at 3:26 PM

$PHAR IEX vol vieze kleine tradertjes:) MSAM 15 oktober 2025 15:54 auteur info Ondanks alle hosannakoersperpectieven: nu kun je ze nog voor € 1,20 verkopen. De komende dagen week niet meer. En dan wachten op de Q3-resultaten

0 · Reply

DARKP00L Oct. 6 at 4:03 PM

$PHAR 11:41 on Oct. 06 2025 Pharming Group Announces Restructuring With 20% Headcount Reduction To Cut Costs By $10M Annually; Anticipates One-Time Restructuring Costs Of ~$7M To Be Recorded In Q4 2025 In Connection With The Headcount Reduction #tradeideas

0 · Reply

Noobnr1 Oct. 6 at 6:40 AM

$NYXH Succes in Texas with thier Genio-system🥂💤🚀 $PHAR $GILD $DVAX $PFE

0 · Reply

Ruconestor Oct. 3 at 9:49 AM

$PHAR

0 · Reply

Pharming Group to report third quarter 2025 financial results and provide business update on November 6

Oct 20, 2025, 2:00 AM EDT - 5 days ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Oct 6, 2025, 11:35 AM EDT - 19 days ago

Pharming Group provides update on previously announced G&A expense reduction plan

Oct 1, 2025, 1:00 AM EDT - 24 days ago

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Sep 10, 2025, 1:00 AM EDT - 6 weeks ago

Pharming Group promoted to the Euronext AMX® index

Sep 3, 2025, 2:00 AM EDT - 7 weeks ago

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 1:00 AM EDT - 7 weeks ago

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Aug 4, 2025, 2:00 AM EDT - 2 months ago

Pharming Group to participate in August investor conference

Aug 1, 2025, 3:04 PM EDT - 3 months ago

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 1:00 AM EDT - 3 months ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Jul 17, 2025, 2:00 AM EDT - 3 months ago

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Jun 24, 2025, 1:00 AM EDT - 4 months ago

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 11, 2025, 11:15 AM EDT - 4 months ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

May 28, 2025, 2:00 AM EDT - 5 months ago

Pharming Group to participate in June investor conferences

May 9, 2025, 8:50 AM EDT - 6 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 6 months ago

Pharming Group reports first quarter 2025 financial results and provides business update

Apr 30, 2025, 11:45 AM EDT - 6 months ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 24, 2025, 2:00 AM EDT - 6 months ago

Pharming Group to report first quarter 2025 financial results on May 8

Apr 23, 2025, 3:30 AM EDT - 6 months ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 3, 2025, 1:00 AM EDT - 7 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Mar 28, 2025, 3:00 AM EDT - 7 months ago

Pharming Group to participate in April investor conferences

Mar 13, 2025, 7:44 PM EDT - 8 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 8 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 4, 2025, 9:15 AM EST - 8 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Feb 7, 2025, 4:00 PM EST - 9 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Jan 21, 2025, 12:00 PM EST - 9 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 1:00 AM EST - 9 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Dec 15, 2024, 1:45 PM EST - 11 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 11, 2024, 9:34 AM EST - 11 months ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Nov 5, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in November investor conference

Oct 24, 2024, 1:44 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 10, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Sep 26, 2024, 1:00 AM EDT - 1 year ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group to participate in September investor conferences

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 8, 2024, 1:00 AM EDT - 1 year ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 4, 2024, 2:30 AM EDT - 1 year ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Gabriel1234 Oct. 23 at 7:09 PM

$PHAR https://www.marketwatch.com/investing/stock/phar

0 · Reply

Gabriel1234 Oct. 20 at 9:57 PM

1 · Reply

Gabriel1234 Oct. 20 at 9:56 PM

0 · Reply

Gabriel1234 Oct. 20 at 9:55 PM

0 · Reply

Gabriel1234 Oct. 20 at 1:55 PM

0 · Reply

Thestocktraderhubzee Oct. 20 at 10:02 AM

0 · Reply

Ruconestor Oct. 15 at 3:26 PM

0 · Reply

DARKP00L Oct. 6 at 4:03 PM

0 · Reply

Noobnr1 Oct. 6 at 6:40 AM

$NYXH Succes in Texas with thier Genio-system🥂💤🚀 $PHAR $GILD $DVAX $PFE

0 · Reply

Ruconestor Oct. 3 at 9:49 AM

$PHAR

0 · Reply

NVDAMillionaire Oct. 3 at 7:21 AM

$PHAR Excellent article that nails exactly where PHAR stands right now. So if you want to update your PHAR knowledge or get acquainted with PHAR, this is a must read. https://beyondspx.com/quote/PHAR/analysis/pharming-s-dual-growth-engines-and-pipeline-propel-rare-disease-leadership-nasdaq-phar

0 · Reply

Ruconestor Oct. 1 at 2:57 PM

$PHAR Aandeel gaat verder knallen. Eindelijk valt alles op z'n plek. Mooi die veiligheid gebleken zelfs voor kleuters!! Wachten is op de diverse andere indicaties Very strong buy for very safe and curing Medicins 👍

0 · Reply

OpenOutcrier Oct. 1 at 12:33 PM

$PHAR (+2.1% pre) Pharming shares up as FDA grants priority review for Joenja in children https://ooc.bz/l/79027

0 · Reply

Gabriel1234 Oct. 1 at 11:13 AM

$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-leniolisib-in-children-with-apds-aged-4-to-11-years-1c5a7bca?mod=mw_quote_news_seemore

0 · Reply

Noobnr1 Oct. 1 at 9:19 AM

$NYXH it’s will be a huge company soon 🚀 $GILD $PFE $PHAR Fast judgement by FDA = approval very soon 🥳🥳

0 · Reply

Longterm007 Oct. 1 at 6:14 AM

$PHAR News: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years https://www.pharming.com/news/pharming-group-announces-us-fda-acceptance-priority-review-supplemental-new-drug-application-leniolisib-pediatric-APDS

0 · Reply

SannieVerraderlijk Sep. 29 at 10:41 AM

$PHAR Recovery from 100% tariff scare.

0 · Reply

Longterm007 Sep. 26 at 12:25 PM

$PHAR Fuck Trump

0 · Reply

ap20 Sep. 26 at 11:28 AM

$PHAR Added early in the US.

0 · Reply

Ruconestor Sep. 26 at 8:36 AM

$PHAR Irish Trade Minister Harris States EU-US Trade Deal Keeps Pharma Tariffs at 15%, Emphasizes Importance of Agreement

0 · Reply

Ruconestor Sep. 23 at 12:26 PM

$PHAR Organisatiepagina weergeven voor Pharming Group. Pharming Group 14.072 volgers 1 w 📢 We're proud to share that we've been promoted to the Euronext AMX Index. This promotion reflects our strong growth momentum and recognition in the market. It’s a meaningful step that enhances our visibility and further strengthens our profile, especially with the investor community. A big thank you to our team and partners for helping us reach this milestone, and to our investors for their continued confidence 🤝. 👉 Read more: https://bit.ly/3VFcAH4

0 · Reply

ap20 Sep. 14 at 6:54 PM

$PHAR OK European team: hoping your index boys will step up this week to own some PHAR. And good luck to your Ryder Cup team. I have read about the sportsmanship and comradery way back when the matches started. I wish it could get back that way…

0 · Reply

Market Cap	1.01B
Revenue (ttm)	297.20M
Net Income (ttm)	-11.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3.98%
Debt to Equity Ratio	0.02

Volume	12,300
Avg Vol	12,536
Day's Range	N/A - N/A
Shares Out	68.52M
Stochastic %K	30%
Beta	0.04
Analysts	Strong Sell
Price Target	$30.67